key: cord-0277724-woh8i2z3 authors: Yang, Kai; Li, Min; Yu, Liang; He, Xiaoyan title: Repositioning linifanib as a potent anti-necroptosis agent for sepsis date: 2022-03-27 journal: bioRxiv DOI: 10.1101/2022.03.24.485557 sha: ece3f35f3bb566789159a014c92e42187ecc970b doc_id: 277724 cord_uid: woh8i2z3 Background Sepsis is a systemic inflammatory syndrome (SIRS) caused by acute microbial infection with high mortality rate. The role of tumour necrosis factor α (TNF-α)-induced necroptosis in promoting the pathophysiology of sepsis has been identified. Effective prevention of necroptosis is expected to improve the prognosis of sepsis patients. Methods We conducted bioinformatics prediction of candidate drugs by analyzing differentially expressed genes of sepsis patients extracted from GEO database, combining library of integrated network-based cellular signatures (LINCS) L1000 perturbation database. Biological experiments based on TNF-α-induced necroptosis in cellular and mouse model were performed to verify the protection of candidate drugs from SIRS. Cell viability was measured by CellTiter-Glo luminescent ATP assay. Effects of linifanib on necroptosis were investigated by western blotting, immunoprecipitation, and in vitro RIPK1 kinase assay. Survival curve analysis of SIRS mice treated by linifanib was performed. Results A total of 16 candidate drugs was screened out through bioinformatics analysis. Our experiments demonstrated that linifanib effectively protected cells from necroptosis and rescued the death of SIRS mice from shock induced by TNF-α. In vitro, linifanib directly suppressed RIPK1 kinase activity. In vivo, linifanib effectively reduced the overexpressed level of IL-6, a good marker of severity during severe sepsis, in the lung of SIRS mice. Conclusion We provide preclinical evidence for the potential clinical utility of linifanib in sepsis. Study of drug repositioning using bioinformatical predictions combined with experimental validations provides novel strategies for the development of sepsis drug. Sepsis is a systemic inflammatory syndrome (SIRS) caused by acute microbial infection, at 30-50% mortality rate though antibiotics are widely applied for the treatment (Choi et al. 2020; Martínez-García et al. ; Iskander et al. 2013) . Given the high morbidity and mortality of sepsis and septic shock, the Surviving Sepsis Campaign was initiated globally to help improve the treatment of sepsis and septic shock (J.-S. et al. 2011) . Consequently, a great effort is needed to find new, and more effective therapeutic agents for sepsis/septic shock (Chiao et al. 2013) . In this study, we sought to employ a systematic drug repositioning (Katsila et al. 2016; Lavecchia and Giovanni 2013) bioinformatics approach to identify novel FDA-approved candidate drugs to treat sepsis (Pushpakom et al. 2019) . We proposed a new approach to identify therapeutic drugs for sepsis from existing small molecular compounds, by investigating the difference of functional pathways and the gene expression profile of blood nucleated cells in patients with sepsis and normal control group. This method comprehensively considers the genome expression profile in the state of sepsis, and finds the drugs to reverse the changes of gene expression through pattern matching. Injury of multiple organs induced by cytokine storm and SIRS underlies sepsis progression with septic shock. The role of Tumour necrosis factor α (TNF-α) -induced necroptosis in promoting the pathophysiology of sepsis has been identified. Necroptosis induced by TNF-α initiates downstream signaling cascades driving the production of a wide array of pro-inflammatory cytokines. Necroptosis mediated SIRS and associated proflammatory cytokine storms are increasingly recognized as an important pathogenic mechanism of sepsis (Duprez et al. 2011; Lei et al. 2014) . Blocking TNF-α-induced necroptosis might be useful in mitigating the cytokine storm and preventing severe sepsis clinically. Thus, effective prevention of necroptosis is expected to improve the prognosis of sepsis patients (Wynn et al. 2008 ). However, no mature inhibitors of necroptosis are currently in clinical use (Moerke et al. 2019) . Therefore, the role of candidate drugs from our previous bioinformatics analysis was verified by the TNF-induced necroptosis cellular model in vitro and the TNF-αinduced SIRS mouse model in vivo in our study. Our study of drug repositioning using bioinformatical predictions combined with experimental validations is expected to provide novel strategies for the development of drug for sepsis. We found three sepsis-related datasets from GEO database. Bioinformatics analysis was carried out on these datasets to determine the differentially expressed genes in sepsis compared with normal state. We identified signaling pathways related to the pathogenesis of sepsis from the literature. Finally, according to the gene expression data in the sepsis-related pathways and the gene expression profile of human cell lines induced by small molecular compounds in L1000 library, a pattern matching method is designed based on Kolmogorov-Smirnov test. For each sepsis-related dataset, the treatment scores of all drugs in L1000 library were calculated, and the drugs were sorted. The top 60 drugs in the three datasets were verified in the CTD database, and the drugs unrelated to sepsis or without information in the database were selected as candidate drugs for sepsis. We identified 16 drugs with potential therapeutic effects on sepsis. The overall flow chart is shown in Figure 1. Figure1 . Experimental design. For the virtual screening for sepsis treatment, sepsis-related signaling pathways and datasets were found from public database. DEGs were extracted using sepsis-related microarrays from the GEO. Sepsis-related gene expression data and gene expression profiles in the L1000 database were used to calculate therapeutic scores to obtain candidate compounds. In the next step of experimental validation, FDA-approved drug linifanib was shown to have therapeutic effects in cellular and animal models of necroptosis. We obtained the gene expression profiles of sepsis patients and healthy subjects from GSE69528, GSE46955 and GSE54514 datasets and performed differential expression analysis. We set P value < 0.05 and identified 7771, 6238, 5564 DEGs from the GSE69528, GSE46955 and GSE54514 datasets. We set |log2FC| > 0.7, and identified the DEGs that were significantly up-regulated or down-regulated in three datasets, and their overlapping DEGs are shown in Figure 2A . The volcanic plots are shown in Figure 2B . The heatmap of the TOP 100 DEGs in each dataset are shown in Figure 2C . (A) Venn diagram shows the overlapping DEGs in the three datasets. (B) Volcano plot shows significantly changed genes in the three datasets. Red and blue plots represent up-and downregulated genes, respectively (|log2FC| > 0.7 and P value < 0.05). Black plots represent the genes with no significant difference. (C) Heatmap of the top 100 DEGs in three datasets. Each row represents a DEG, each column represents a sample. The color ratio indicates the relative level of DEG expression: blue, lower than the reference expression, red, higher than the reference expression. This study searched the sepsis-related literature from the biomedical database, and identified 17 signaling pathways related to the pathogenesis of sepsis or important for the prognosis of sepsis patients, as shown in Table 2 . These pathways may contain key pathogenic genes of sepsis, and the expression of these genes is different in patients with sepsis and healthy subjects. Therefore, it is necessary to focus on the gene sets involved in these signaling pathways and take them as the feature pathways of sepsis. We integrated the logFC of DEGs in the three datasets with the genes in each pathway, and calculated the average value of logFC of all genes as the result of up-regulation or downregulation of each pathway. Finally, we calculate the average value of logFC of the pathways corresponding to the three datasets, as shown in Table 2 . We can see that the upregulation of TNF signaling pathway is the highest. We used the gene expression information of three datasets to calculate the therapeutic score, so we got three drug lists. First, these drugs were validated in a public database. The Comparative Toxicogenomics Database(CTD) provides information on the relationship between genes, compounds and diseases (Allan et al. 2018) . In this study, we used CTD to query the association between compounds and sepsis. The drug lists of three datasets GSE46955, GSE69528 and GSE54514 were sorted, and the top 60 drugs were selected and verified in CTD. Drugs were divided into four categories: associated with sepsis, no compounds in CTD, no disease data with compounds, and not associated with sepsis. They are all candidate drugs for potential treatment of sepsis except drugs related to sepsis. The distribution of top 60 drugs of the three datasets is shown in Table 3 . have not yet been reported while no information for 2 drugs ( WH-4-025, XMD-1150) is available. The overlap of candidate drugs is shown in Figure 3 . Necroptosis plays a significant role in the pathophysiology of SIRS and sepsis. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and RIPK1 kinase inhibitors show promise in alleviating or preventing a SIRS response. Our study found that the expression of RIPK1, RIPK3 and MLKL in peripheral blood nucleated cells of sepsis patients was significantly higher than that of healthy controls( Figure 4A ). These results provided a useful reservoir for further experimental verification.To further explore the potential novel therapy target of our bioinformatics predictions, we performed a phenotypic screen for drugs analysis as inhibitors of TNF-α-induced necroptosis in FADD-deficient Jurkat cells. FADDdeficient Jurkat cells were pretreated with or without these compounds (10 μM, 30 min) and then stimulated with 50ng/ml TNF-α for 24 h or left untreated (Lawrence and Chow 2005) . Nec-1 was used as positive control to monitor RIPK1 kinase dependency in the induced necroptosis. (Moriwaki and Chan 2014) . Cell viability was determined using the ATP-based CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Measurements were normalized to those in untreated control cells (100%) ( Figure 4B ). Our study demonstrated that 1 (linifanib) of 16 candidate drugs protected effectively cells from necroptosis (Figure4 C-E). We further performed dose-response curves to quantitatively assess the inhibitory potency of linifanib. Drug toxicity of linifanib was assessed by determining the half maximal inhibitory concentration (IC50), which was 114.2 uM in FADD-deficient Jurkat cells( Figure 4F ) and 51.3 uM in MEFs cells( Figure 4G ). In addition, the half maximal effective concentration (EC50) for inhibiting necroptosis in this setting was measured to be 5.13μM in human FADD-deficient Jurkat cells ( Figure 4H ), 0.14 uM in MEFs cells ( Figure 4I ). Highlighting the window of opportunity for necroptosis inhibition. Taken together, these data demonstrated that linifanib efficiently blocked TNF-α-induced necroptosis in both human and murine cells, was a potent necroptosis inhibitor. We found that the protective effect of linifanib in TNF-α-induced necroptosis was as potent as that of the well-established but not clinically applicable RIPK1 inhibitor Nec-1 (Riebeling et al. 2020) . We next evaluated whether the inhibitory mechanism of linifanib on necroptosis requires the involvement of RIPK1. FADD-deficient Jurkat cells were pretreated with 4μM linifanib or 25μM Nec-1 for 30min followed by treatment with or without TNFαfor indicate time points. Linifanib selectively inhibited the phosphorylation RIPK1 and MLKL when necroptosis was induced by TNF-αin FADD-deficient Jurkat cells( Figure 5A ). Similar results were also obtained in murine MEFs cells ( Figure 5B ). Thus, these results indicate that linifanib inhibits TNF-α-induced phosphorylation of RIPK1 and MLKL. TNF-αcan rapidly activate TNFR1 upon binding, thereby inducing the recruitment of RIPK1, TAK1 to TNFR1 to form a TNFR1 signaling complex (TNF-RSC or complex I) (Song et al. 2021; Fan et al. 2011; Lei et al. 2014) . Analysis of complex I formation influenced by linifanib was performed immunoprecipitated(IP)after stimulation with anti-TNFR1 antibody FLAG-tagged TNF-αusing mouse primary fibroblastic cells (Riebeling et al. 2020; Nakazawa et al. 2016) . We found that the recruitment of RIPK1 into the TNF-RSC was largely blocked in TNF-αstimulated-MEFs by linifanib. In addition, the recruitment of TAK1 was increased in linifanib-pretreated MEFs( Figure 5C ). As linifanib suppressed active RIPK1 kinase-mediated necroptosis and SIRS in response to TNF-α. We then conducted an in vitro kinase assay to further test the potency of linifanib directly inhibit RIPK1. Quantification of ADP-Glo kinase assay showed that linifanib suppressed recombinant hRIPK1(Rojas-Rivera et al. 2017) kinase activity (IC 50 = 1182 nM) ( Figure 5D ). These data demonstrated molecular mechanisms by which linifanib protect cells from TNF-induced necroptosis. As demonstrated by an in vitro kinase assay, linifanib directly suppressed the kinase activity of RIPK1. Our foundings indicated that linifanib is as effective as the well established RIPK1 inhibitor Nec-1 in preventing necroptosis and is a RIPK1 kinase inhibitor. To explore whether linifanib protects against inflammation in vivo, we tested it in the TNF-induced SIRS model (Duprez et al. 2011) . Linifanib (50mg/kg) or Nec-1 (30mg/kg), a positive control as an effective inhibitor of necroptosis, given by intragastric gavage 30 min before i.v. injection of mTNF-α, protected mice from hypothermia and death (Figure 6 A,B). Since interleukin 6 (IL-6) level in vivo correlated well with TNF alpha serum level and the mortality rate of patients with septic shock (Hou et al. 2015; Dama et al. 1992; Shahkar et al. 2011), we detected the expression level in the lung of SIRS mice. Our data showed that the SIRS mice showed significantly higher levels of IL-6 expression in the lung tissue at 6 hours after the mice received the TNFA injection in the tail vein, compared with normal control mice. And the overexpressed IL-6 of SIRS mice was significantly suppressed by pretreatment with linifanib. Thus, these results demonstrate that linifanib protects against TNF-induced SIRS in vivo. Sepsis is a life threatening health condition which occurs due to the severe and systemic inflammatory response to infection (Kingsley et al. 2020 ). The syndrome is initially characterized by dysregulated inflammatory, namely systemic inflammatory response syndrome (SIRS), progressing to severe sepsis and septic shock (Mayr, Yende, and Angus 2014) . Sepsis is the most common cause of death for critically ill patients in non-coronary intensive care units (Angus et al. 2001) . Necroptosis, leading to enormous release of inflammatory mediated and exacerbates inflammation, plays a vital role in the pathophysiology of systemic sepsis (Duprez et al. 2011; Hu et al. 2018) . TNF-α, cytokine that plays a key role in sepsis, triggers necroptosis in response to tissue injury and inflammation (Xagorari, Roussos, and Papapetropoulos 2010) . The most pertinent information regarding necroptosis was derived from studies of TNF-α induced necroptosis (Junying et al. 2019; Chen et al. 2014; Shan et al. 2018 ). Using a bioinformatics analysis and the drug repositioning strategy, we predicted a set of potential drug candidates for sepsis and validated the effectiveness of drug using both in vitro and in vivo models of TNF-α-induced necroptosis. Our experimental validation found that the candidate drug linifanib effectively inhibited necroptosis, SIRS and related tissue damage. This research makes the following features. Firstly, we predict therapeutic drugs by analyzing the differences of gene expression in patients with sepsis. This bioinformatics prediction is an efficient drug screening method compared with traditional experiments. Secondly, by analyzing the pathophysiological molecular mechanism that plays an important role in sepsis, this study established an effective experimental verification system for the drug candidates predicted by bioinformatics. Thirdly, in this study, LINCS database containing FDA approved drug library was used, and then linifanib was repurposed to inhibit necroptosis, related inflammatory and SIRS. Since the safety evaluation of the drug has been completed, it is expected to be quickly transformed into clinical application. This provided further evidence that necroptosis plays a significant role in the pathophysiology of sepsis. Thus, RIPK1-dependent necroptosis may be a potential novel therapy target of sepsis. Quantification of ADP-Glo kinase assays were performed with recombinant hRIPK1 in the presence of increasing concentrations of linifanib in our study. We found that linifanib inhibited the kinase activity of RIPK1 dose dependently, with an EC50 of 1182 nm, which was lower than that of the necroptosis inhibitor Nec-1 as a positive control. This indicates that linifanib may directly suppress RIPK1 kinase activity with excellent prospects for clinical application. Necroptosis is characterized by marked swelling of cell, rupture of the plasma membrane and subsequent DAMPs released after a cellular disruption (Wang et al. 2015) . TNFα-induced necroptosis initiates downstream signaling cascades driving the production of a series of pro-inflammatory cytokines including IL-6( Kearney et al. 2015) . Elevated blood concentrations of IL-6 triggered a detrimental cytokine storm (Chen et al. 2020 ) in sepsis were negatively correlated with the poor prognosis of patients (Chen et al. 2013 ). Endothelial cell necroptosis may contribute to lethality in both SIRS and sepsis patients (Zelic et al. 2018 ). Therefore, we adopted the SIRS mice model induced by tail vein injection of TNF-α to verify the role of candidate drugs from our previous bioinformatics analysis. Our study found that linifanib can effectively rescue the shock death and inhibit the overexpressed level of IL-6 mRNA in the damage lung tissue of SIRS mice. These data provide a solid basis for the clinical application of linifanib in the treatment of sepsis. This study had two limitations. Firstly, despite recent research progress, our understanding of SIRS pathogenesis is still incomplete. More studies in the pathophysiological mechanism of sepsis and verification systems for therapeutic targets of sepsis are also needed. Secondly, whether linifanib can inhibit sepsis-related inflammatory response and reduce the mortality in patients need to be proved by clinical trials. However, linifanib is expensive before invalidation of the patents existed, thus limiting its current application in investigator-initiated clinical trials and translational research. In conclusion, linifanib was demonstrated to inhibit RIPK1-dependent necroptosis and attenuate SIRS-induced acute lung injury. The present results provide further basis for the repurposing of linifanib to decrease sepsis mortality. Drug prediction Data collection. In order to predict new drugs for the treatment of sepsis, we performed bioinformatics analysis based on gene expression data of sepsis. The datasets associated with sepsis were retrieved and downloaded from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) database by setting the keyword as "sepsis", organism as "Homo sapiens", and study type as "expression profiling by array". The datasets included in this study need to meet the following criteria: 1) the dataset should be human gene expression characteristics: and 2) gene expression data should be generated from sepsis patients and healthy subjects. Finally, the datasets GSE69528 (Pankla et al. 2009 ), GSE46955 (Shalova et al. 2015 ) and GSE54514 (Parnell et al. 2013) were selected, as shown in It contains 978 landmark genes and 9196 high fidelity inferred genes from 11350 inferred genes. There are 10174 genes in this gene set, which is also the gene set used in drug prediction. The LINCS data used in this study is the level 5 data "gse70138_broad_lincs_level5_compz_n1180 50x12328. Gctx. GZ" of GSE70138. For each experimental group, calculate the gene differential expression value under each perturbation experiment of small molecular compounds, the differential expression values are arranged from large to small. The perturbation data of each small molecular compound includes the gene expression data of different cell lines after different doses and different times of treatment. Kolmogorov-Smirnov test. In statistics, Kolmogorov-Smirnov test(KS test) is a nonparametric test, which is based on cumulative distribution function to test whether an empirical distribution conforms to a theoretical distribution or compare whether there is significant difference between two empirical distributions (Hollander, Wolfe, and Chicken 2013; Lamb et al. 2006 ). X1, X2,…, Xm, Y1, Y2,…, Yn are two independent random samples, and the distribution functions are ( ) and ( ), they can be defined as: Where m and n denote the number of samples in the two groups, t denotes any real number, [−∞, ] ( ) and [−∞, ] ( ) are defined as: 1, ≤ 0, > . (4) And the statistic of KS test is defined as: Where is the supremum of distance. The statistic of Kolmogorov Smirnov test quantifies the distance between the empirical distribution functions of two groups of samples. null hypothesis H0: the two data distributions are consistent or the data conform to the theoretical distribution. When the actual observed value , is greater than the critical value, H0 is rejected, otherwise, H0 is accepted. Calculation of the therapeutic scores. We use the differential expression information of genes in sepsis-related pathways to construct disease signatures, and use the differential expression information of genes under the action of drugs to construct drug signatures. The differential expression values of genes in sepsis-related pathways came from log-fold change (logFC) after differential expression analysis of sepsis-related datasets, and the gene differential expression information under the action of drugs comes from L1000 library. Based on the statistic of KS test, these disease signatures and drug signatures are used to design a pattern matching method to calculate the treatment scores of different drugs on sepsis. For sepsis-related signaling pathway C and drug-induced gene expression profile D, the treatment scores of up-regulated gene set and down-regulated gene set of pathway C relative to drug-induced gene expression profile D were calculated respectively. Firstly, take the intersection of up-regulated genes or down-regulated genes in sepsisrelated pathways and genes under drug perturbation, record this gene set as H. The genes induced by drugs were arranged according to the differential expression value from large to small, and the genes in H were arranged from large to small according to this differential expression value. Using the statistic of KS test, a and b are defined as follows: Where N is the total number of genes in the H gene set, and M is the total number of genes whose expression value changes under drug perturbation, and P is the position of current gene g in gene set H, and Q is the position of gene g in the gene list under drug perturbation. Therefore, the treatment score of up-regulated gene set or down-regulated gene set in pathway C is calculated as And the treatment score of drug for sepsis-related signaling pathway C is calculated as Where c denotes the sepsis-related signaling pathway and d denotes the drug. There are four possible effects of drugs on a sepsis-related signaling pathway. In the first case, the change of gene expression under drug perturbation is opposite to that under sepsis, so this drug has the potential to treat sepsis, in this case, , < 0. In the second case, for the genes whose expression value decreases in sepsis, under drug perturbation, the expression value of some genes increases and the expression value of others decreases. Then the use of the drug in sepsis will cause the expression of some genes to return to normal, but the expression of other genes will continue to decrease. In the third case, for genes with increased expression value in sepsis, under drug perturbation, the expression value of some genes increases and the expression value of others decreases. Then the use of the drug in sepsis will cause the expression of some genes to return to normal, but the expression of other genes will continue to increase. In the fourth case, the gene whose expression value increases or decreases in sepsis also increases or decreases under the action of the drug, indicating that the effect of the drug and sepsis on gene expression changes is consistent, and the drug may aggravate the severity of sepsis, in this case, , > 0. In the first and fourth cases, , * , < 0. After screening the drugs that meet these two conditions, the drugs meeting the first condition were further screened according to , < 0. The greater the absolute value of , , the more obvious the effect of the drug. After calculating the drug score for each pathway, further processing was performed: Scores obtained by treating the same cell line with a drug at different times and doses, Only the results with the largest absolute score are retained, scores obtained by treating different cell lines with a drug, the mean value of the score was calculated and its absolute value was used as the treatment score of the drug. For each sepsis-related dataset, the average score of each drug in all pathways was calculated. Only results with score < 0 are retained, and sorted according to absolute value of the score from large to small, including only the drugs with potential therapeutic effect on sepsis. Finally, take the overlapping parts of the Top60 drug list of three datasets to determine the final candidate drugs. Biological reagents. The reagents used were as follows: Vazyme) and analyzed with CFX Manager software of Bio-rad CFX384. Relative gene expression was normalized to 18s and determined using the -ΔΔCT method. The primer sequences were as following: for 18s, forward: 5′-AGTCCCTGCCCTTTGTACACA-3′ and reverse 5′ -CGATCCGAGGGCCTCACTA-3′ ; for IL-6, forward: 5′ -TACCACTCCCAACAGACCTG-3′ and reverse 5′-GGTACTCCAGAAGACCAGAGG -3′. Western blotting analysis. Cells were lysed in 1% NP-40 buffer for total lysis (1% Nonidet P-40, 50 mM Tris Base (pH 7.5), 150 mM NaCl, 1 mM PMSF, 1 mM NaF/Na3VO4, Pierce Protease Inhibitor Tablets). All cell lysis buffers were supplemented with 1% NP-40 buffer to the same concentration and were then added with 5x loading buffer (10% SDS, 40% glycerol, 25% 1M 336 Tris6 -HCl (pH 6.8), 0.005% bromophenol blue, 25% β-Mercaptoethanol) with denaturation at 95℃ for 5 min. Cell lysates were analysed by SDS-PAGE gels with running buffer and subsequently transferred onto immobilon-NC transfer membrane (NC membrane, HATF00010, Millipore) or 0.45 μM polyvinylidene difluoride membrane (PVDF membrane, MXHVWP124, Millipore). Membranes were blocked in 5% skim milk in Tris-buffered saline (TBS) containing 0.1% Tween 20 before overnight incubation with specific primary antibodies at 4℃. All listed primary antibodies were used at 1:1000. Membranes were then washed and incubated with appropriate HRP-conjugated secondary antibodies (1031-05 and 4050-05, SouthernBiotech), developed immunoreactivity (G2014-50ML, Servicebio), and imaged using the Tanon-4800 345 (Tanon Science & Technology Co., Ltd.). For immunoprecipitation (IP) of complex I, MEFs were lysed by 1% NP-40 buffer (1% Nonidet P-40, 50 mM Tris Base (pH 7.5), 150 mM NaCl, 1 mM PMSF, 1 mM NaF/Na3VO4 and Pierce Protease Inhibitor). Complex I was purified by IP using ANTI-FLAG® M2 Affinity Gel of 20ul. The IP protein was rotated overnight in 4℃. The beads were washed three times with ice-cold 4% NP-40 buffer and eluted by directly adding 2x loading buffer (4% SDS, 20% glycerol, 10% 1 M Tris-HCl (pH 6.8), 0.005% bromophenol blue, 10% b-Mercaptoethanol) in 95℃ for 5 min, then analyzed by immunoblotting (antibodies used as indicated). In vitro kinase assays. We followed the protocol of RIPK1 Kinase Enzyme System (Promega, Cat#VA7591) and ADP-Glo™ Kinase Assay (Promega, Cat# V6930) to detect the inhibition of RIPK1 kinase activity by linifanib. Data and statistical analysis. The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology. Results are presented as means ± SEM. Student's t-test and one-way ANOVA were used for comparison among the different groups. The log-rank (Mantel-Cox) test was performed for survival curve analysis using GraphPad Prism8.0. P < 0.05 was considered statistically significant. Proceedings of the National Academy of Sciences of the United States of America. 2019. 'Targeting RIPK1 for the treatment of human diseases The Comparative Toxicogenomics Database: update Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation Clinical and immunological features of severe and moderate coronavirus disease Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death P2X7 receptor activation contributes to an initial upstream mechanism of lipopolysaccharide-induced vascular dysfunction Exosome-based delivery of super-repressor IκBα relieves sepsis-associated organ damage and mortality Cytokine serum level during severe sepsis in human IL-6 as a marker of severity The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsisrelated acute respiratory distress syndrome RIP Kinase-Dependent Necrosis Drives Lethal Systemic Inflammatory Response Syndrome USP4 targets TAK1 to downregulate TNFα-induced NF-κB activation LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent Nonparametric statistical methods Accuracy of serum interleukin (IL)-6 in sepsis diagnosis: a systematic review and metaanalysis The Emerging Role of Stimulator of Interferons Genes Signaling in Sepsis : Inflammation Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding Activated protein C inhibits high mobility group box 1 signaling in endothelial cells Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases Computational approaches in target identification and drug discovery Necroptosis suppresses inflammation via termination of TNF-or LPS-induced cytokine and chemokine production The library of integrated network-based cellular signatures NIH program: system-level cataloging of human cells response to perturbations Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Virtual screening strategies in drug discovery: a critical review FADD deficiency sensitises Jurkat T cells to TNFα-dependent necrosis during activation-induced cell death Transforming growth factor β-activated kinase 1 signaling pathway critically regulates myocardial survival and remodeling P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis Epidemiology of severe sepsis Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target The anticonvulsive Phenhydan® suppresses extrinsic cell death Necrosis-dependent and independent signaling of the RIP kinases in inflammation Linear ubiquitination is involved in the pathogenesis of optineurin-associated amyotrophic lateral sclerosis Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis Identifying key regulatory genes in the whole blood of septic patients to monitor underlying immune dysfunctions Drug repurposing: progress, challenges and recommendations %J Cell Death Krautwald, and Differentiation. 2020. 'Primidone blocks RIPK1-driven cell death and inflammation When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157 A Phase I/II Trial of Carfilzomib The role of IL-6 for predicting neonatal sepsis: A systematic review and meta-analysis Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α Necroptosis in development and diseases Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development A next generation connectivity map: L1000 platform and the first 1,000,000 profiles Effects of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Blood Flow in Optic Nerve Head in Rabbits and Axonal Regeneration of Retinal Ganglion Cells in Rats E2F1-regulated miR-30b suppresses Cyclophilin D and protects heart from ischemia/reperfusion injury and necrotic cell death Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists Inhibition of LPS-stimulated pathways in macrophages by the flavonoid luteolin Dexmedetomidine attenuates oxidative/nitrative stress in lung tissues of septic mice partly via activating heme oxygenase1 RIP kinase 1-dependent endothelial necroptosis underlies systemic inflammatory response syndrome Thanks to all those who maintain excellent databases and to all experimentalists who enabled this work by making their data publicly available. We would like to thank Dr. Hongbing Zhang of Peking Union Medical College for his mentoring and guidance in the field of drug repurposing. This work was supported by the National Natural Science Foundation of China The authors declare no competing interests.